Application of cerebroside B compound

A technology of cerebrosides and compounds, which is applied in the field of preparation of drugs for the treatment of post-ischemic brain injury, can solve problems such as separation and purification difficulties, and achieve significant therapeutic effects, high purity, and the effect of reducing the size of cerebral infarction

Inactive Publication Date: 2012-06-20
NANJING MEDICAL UNIV +2
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Coupled with its similar structure, it brings gre

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cerebroside B compound
  • Application of cerebroside B compound
  • Application of cerebroside B compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The method for preparing cerebroside A and cerebroside B from Gallus pilosulae, the concrete steps are:

[0034] (1) Grinding: Grinding the dried sample of Gallinarum albuminosa (1.5 kg) (Yanyuan County, Sichuan Province) to 100-10 meshes;

[0035] (2) Solvent extraction: put the pulverized Gallus firji into a 15-liter container, and use methanol (7.5 L) to vibrate and leach in a shaker for 3 days to obtain the extract of Gallinarum gallinarum (151.3 g); Then, solvent partition the extract with 90% aq. MeOH and n-hexane. Concentrate the obtained 90% aq. MeOH solution and perform solvent partition with water and n-butanol. The n-butanol solution is concentrated under reduced pressure to obtain n-butanol layer sample (16.0 g);

[0036] (3) Separation and purification: use an ODS open column for n-butanol layer samples (the solvent system is MeOH:H 2 O=90:10, 95:5, 100:0); then, the sample containing the target compound (95% aq. MeOH fraction, 1.3 g) was separated on a S...

Embodiment 2

[0039] The physicochemical characteristics and the qualitative identification of chemical structure of cerebroside A and cerebroside B that embodiment 1 obtains:

[0040] Physicochemical properties of cerebroside A: [α] 25 D+ 4.5 (c 0.46, MeOH); Infrared spectrum (KBr) values: 3371, 2921, 2853, 1643, 1536, 1468, and 1081 cm-1; m / z ( 73.46), 71.20 (71.17), 70.81 (70.71), 70.25 (70.20), 68.86, 61.33 (61.21), 53.04 (53.00, CH-ND-), 39.90, 34.53, 32.23, 31.736, 28.194, 94 , 27.38, 24.61, 22.14, 15.83, and 13.95.

[0041] Cerebroside B: The chemical structure of cerebroside B was determined using the same method as the chemical structure of cerebroside A, and it was found that the structure (including the three-dimensional structure) of cerebroside B and A differs only in that B is in the fatty chain There are two more methylene groups than A. Physicochemical properties of cerebroside B: [α] 25 D + 2.0 (c 0.46, MeOH), m / z 756 (M+H)+, the infrared spectrum value and chemica...

Embodiment 3

[0043] Cerebroside A of the present invention ( JNGZ-A) and cerebroside B ( JNGZ-B) Animal pharmacology experiments were carried out to prove its application in the preparation of drugs for treating post-ischemic brain injury.

[0044] The degree of neurological damage due to different forms of cerebral ischemia varies. The main pathological manifestations of middle cerebral artery occlusion are infarction and cerebral edema in the striatum, cerebral cortex, and hippocampus, which have a very high mortality and disability rate. Global cerebral ischemia selectively damages central nervous cells sensitive to hypoxia (such as nerve cells in the CA1 area of ​​the hippocampus), resulting in memory loss. Therefore, the present invention will use the classic middle cerebral artery occlusion (middle cerebral artery occlusion, MCAO) operation to simulate stroke, and use the vertebral artery and common carotid artery clipping operation to establish an animal model of global cerebral...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of cerebroside B which is extracted and prepared from termitomyces in preparing a medicine for treating ischemic brain injury. The application proves that a cerebroside compound has obvious treatment function on ischemic brain injury through pharmacology experiments, can reduce the cerebral infarction area which is caused by cerebral ischemia and relieve the cerebral edema through a blood-brain barrier, reduce the death of nerve cells, and simultaneously promote recovery of movement and cognitive functions after cerebral apoplexy, so the death rate of the cerebral apoplexy is reduced. The application develops the new medicine application of the cerebroside compound, and new therapeutic drugs are provided for treating diseases of the cerebral apoplexy.

Description

[0001] (This case is a divisional application with application number: 200910154675.0, titled Application of a Cerebroside Compound). technical field [0002] The invention belongs to the field of natural medicinal chemistry. The invention mainly relates to the application of cerebroside compound extracted from Gallus pilosulae in the preparation of medicine for treating post-ischemic brain injury. Background technique [0003] Cerebral ischemic disease is one of the most common clinical diseases, with the characteristics of high morbidity, disability and mortality, which seriously threatens human health. With the gradual aging of the world's population, the incidence of ischemic brain injury is increasing year by year, but so far there is still a lack of effective prevention and treatment measures at home and abroad. The high sensitivity of central nervous cells to hypoxic injury and the lack of regenerative ability are considered to be the main reasons for the sequelae of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7032A61P9/10C07H15/10C07H1/08
Inventor 陈玲戚建华戚智白银阳孙恺悦张卓高丽娟
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap